SLC5A2 and type 2 diabetes mellitus: DKA developed in 38% of patients treated with SGLT-2 inhibitors, with the median blood glucose value being 13.5 mmol/L compared to 2% of patients using other medical treatments for type 2 diabetes, with the median glucose value here being 25.4 mmol/L [41].